A Phase 3 clinical trial involving gonadorelin was updated on September 11, 2026. The trial, registered as NCT07816562 and titled "Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)," is currently listed with a status of recruiting.
This study is evaluating ovulation trigger strategies in patients with low ovarian reserve. Gonadorelin is an approved compound being examined within the context of this trial's design. The trial is in Phase 3, according to the registry entry.
No outcome data, efficacy results, or safety findings have been reported for this trial at this stage. The current update reflects only the recruiting status as listed on the trial registry. Further information about the trial's design, timeline, and eligibility can be found through the official clinical trial listing.
Readers interested in learning more about gonadorelin, including its approved regulatory status and general background, can consult the compound overview for additional context.